NASDAQ: IART · Medical Devices
Integra LifeSciences (IART) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Integra LifeSciences (IART) at $16.00 a share. The stock last closed at $13.98, which puts the model's fair value 14.4% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. Integra LifeSciences Holdings Corporation.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $13.16 to $16.00 (+21.6%). The multiple the model anchors on moved, lifting the fair value: most of the move.
What the model makes of itThe price of $13.98 is 14.4% below it: Fairly valued, on a medium evidence grade.
What's nextNext report on 25 Feb 2027. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give IART?
The calibrated range for IART over 63 trading days is $12.80 to $19.01. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $8.99 to $23.63. In 57% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments.
Faircurve's model gives a fair value of $16.00 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $13.16, so the fair value moved +21.6%. The model says the multiple it anchors on moved, lifting the fair value: most of the move. The calibrated range over 63 trading days is $12.80 to $19.01. There is no live options data for the stock, so the range is built from the fair value and calibrated weekly against realised prices, from 13,250 past valuations. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium, based on input completeness, the number and agreement of comparable companies, and the width of outcomes. It does not say whether the fair value is right.
Integra scores 57 out of 100 on quality against comparable companies. Profitability stands out at 87, with ROIC of 14.6% against a peer median of -3.2%. The balance sheet scores 10, with net debt to EBITDA of 7.49x against a peer median of 4.50x. The model compares Integra with Artivion, Inc. (AORT), Enovis Corporation (ENOV), Cytek Biosciences, Inc. (CTKB) and UFP Technologies, Inc. (UFPT).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does IART report earnings, and how has the stock reacted?
Integra LifeSciences's next earnings report is scheduled for 25 Feb 2027. Companies can move their dates.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across IART's last 8 reports, ignoring direction, was 7.3%.
How does IART score on business quality?
Integra LifeSciences's overall quality score is 57 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 87 | 14.6%ROIC | -3.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 78 | 5.50xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 32 | 1.5%Revenue growth, trailing | 10.9% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 64 | 0.0%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 10 | 7.49xNet debt / EBITDA | 4.50x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 14 | 14.0 ptsEBITDA margin downside volatility, 5y | 4.6 pts |
How does IART compare with similar companies?
The companies in medical devices closest to Integra LifeSciences in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| AHCO AdaptHealth Corp. | $7.73 | $7.47 | -3.4% | Low evidence grade |
| AORT Artivion, Inc. | $18.47 | $20.28 | +9.8% | Fairly valued |
| TNDM Tandem Diabetes Care, Inc. | $18.48 | $21.89 | +18.5% | Low evidence grade |
| CNMD CONMED Corporation | $49.35 | $50.43 | +2.2% | Low evidence grade |
| ENOV Enovis Corporation | $27.92 | $32.77 | +17.4% | Undervalued |
| CTKB Cytek Biosciences, Inc. | $5.63 | $6.03 | +7.1% | Fairly valued |
| INSP Inspire Medical Systems, Inc. | $59.12 | $61.27 | +3.6% | Low evidence grade |
| UFPT UFP Technologies, Inc. | $298.54 | $266.65 | -10.7% | Fairly valued |
What the comparable companies' multiples alone would give for IART, the peer-implied price, is $24.06 a share on this run. The fair value weighs that against the company's own multiple.
Integra LifeSciences at a glance
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments.
- Market value
- $1.1B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $1.7B
- Consensus revenue growth, next fiscal year
- +0.5%
- Analysts with estimates
- 7
- Beta to the US market
- 1.26
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. IART was among them.
How the fair value is worked out: the model prices Integra LifeSciences on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for IART was $13.16. As of 14 Nov 2026 it is $16.00, a change of +21.6%. The multiple the model anchors on moved, lifting the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Integra LifeSciences's valuation
Is Integra LifeSciences stock undervalued or overvalued?
On Faircurve's model, IART reads as Fairly valued as of 14 Nov 2026. The model's fair value is $16.00 a share against a last close of $13.98, a gap of +14.4%.
What is IART's fair value?
$16.00 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $8.99 to $23.63.
What price range does the model give IART?
$12.80 to $19.01 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.
When does Integra LifeSciences report earnings next?
The next report is scheduled for 25 Feb 2027. Companies can move their dates.
How much has IART moved on past earnings reports?
Across its last 8 reports the median two session move was 7.3%, ignoring direction. The largest was +31.5% around the report of 5 May 2026.
How confident is the model in this valuation?
The model's evidence grade for IART is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on IART
The model holds no idea open on IART today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on IART with their outcomes. A free account is enough.